All In Biotech

Drug Trial Radar · NCT04423393

Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection

A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

May 26, 2020

Primary completion

Oct 24, 2022

Study completion Nov 25, 2022

Sponsor

Lead sponsor
Vir Biotechnology, Inc.Industry
Sponsor type
Industry
First posted
Jun 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).

Conditions

  • Chronic Hepatitis B

Interventions

  • VIR-3434Biological

    VIR-3434 given by subcutaneous injection or intravenous infusion.

  • PlaceboOther

    Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Treatment-emergent period, which is up to Week 24 in part A, and up to Week 8 in part B/C/D
  2. Number of Participants With Clinical Laboratory AbnormalitiesTime frame: Up to 280 days post-dose

Locations

24 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigative Site

    Essen, Germany

  • Investigative Site

    Frankfurt, Germany

  • Investigative Site

    Hanover, Germany

  • Investigative Site

    Leipzig, Germany

  • Investigative Site

    Mainz, Germany

  • Investigative Site

    Mannheim, Germany

  • Investigative Site

    Ulm, Germany

  • Investigative Site

    Hong Kong, Hong Kong

  • Investigative Site

    Auckland, New Zealand

  • Investigative Site

    Havelock North, New Zealand

  • Investigative Site

    Newtown, New Zealand

  • Investigative Site

    Tauranga, New Zealand

  • Investigative Site

    Bucharest, Romania

  • Investigative Site

    Singapore, Singapore

  • Investigative Site

    Singapore, Singapore

  • Investigative Site

    Busan, South Korea

  • Investigative Site

    Busan, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Seoul, South Korea

  • Investigative Site

    Birmingham, United Kingdom

  • Investigative Site

    London, United Kingdom

  • Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.